Manufacturer Lilly has announced plans to hike the amount it charges private providers in the UK to bring it into line with ...

SHOPPING: Shedding unwanted pounds no longer has to be a challenge thanks to this affordable alternative to Ozempic that's ...

This episode of Pharma Pulse explores AbbVie’s $195 million investment to expand US API production, new survey results ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

There is zero evidence that ​​semaglutides can increase the size of your crown jewels. What may happen is that as you lose ...

Surging medical costs, pricey new drugs, and the looming end of enhanced subsidies could push ACA Marketplace premiums to ...

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...